Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New heart ablation waveforms aim to tame atrial fibrillation

NCT ID NCT07444320

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Aug 28, 2026 · Updated 5 times

Summary

This study tests new waveforms delivered by the FARAPULSE PFA system to treat atrial fibrillation, a common heart rhythm problem. About 200 adults with paroxysmal or persistent atrial fibrillation will receive the procedure. The goal is to see if these new waveforms are safe and can effectively isolate the pulmonary veins and posterior wall of the heart to restore normal rhythm.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
FARAPULSE Pulsed Field Ablation (PFA) System (device)
What this could lead to
If successful, this could offer a safer, more precise way to treat atrial fibrillation, potentially reducing complications and improving outcomes.
What could go wrong
This is an early feasibility study with only 200 participants, so results may not apply to everyone. There are risks of procedure-related complications like bleeding or heart rhythm issues.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2026

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. ≥ 18 years of age, or older if required by local law 2. Persistent Atrial Fibrillation or Paroxysmal Atrial Fibrillation 1. Persistent AF Documented: * Physician's note confirming the presence of persistent atrial fibrillation and the arrhythmia symptoms * Within 180 days prior to Enrollment: A 24-hour continuous ECG recording confirming continuous AF OR Two (2) ECGs from any regulatory-cleared rhythm monitoring device showing continuous AF taken at least 7 days apart. OR 2. Paroxysmal AF Documented: * Physician's note confirming the presence of paroxysmal atrial fibrillation and the arrhythmia symptoms * Within 180 days of the Enrollment Date, one (1) ECG from any regulatory-cleared rhythm monitoring device showing atrial Fibrillation (AF) 3. Willing and capable of providing informed consent 4. Willing and capable of participating in all follow-up assessments and testing associated with this clinical investigation at an approved clinical investigational center Exclusion Criteria: 1. Atrial exclusions - any of the following atrial conditions: 1. Left atrial anteroposterior diameter ≥ 5.5 cm, or if LA diameter is not available, LA non-indexed volume \> 100 mL. If both values are available, only the LA diameter will be used to confirm eligibility. 2. Any prior atrial endocardial, epicardial, or surgical ablation procedure for arrhythmia other than ablation for right-sided SVT or cavotricuspid isthmus ablation 3. Any prior atrial surgery 4. Current atrial myxoma 5. Current Left Atrial Thrombus 6. Any PV abnormality, stenosis, or stenting (common and middle PVs are admissible) 2. Cardiovascular Conditions - Any of the following cardiovascular conditions: 1. History of sustained ventricular tachycardia (VT) or any ventricular fibrillation (VF) 2. Atrial fibrillation that is secondary to electrolyte imbalance, thyroid disease, alcohol, or other reversible/non-cardiac causes 3. Cardiac Devices and Implants: * Current or anticipated pacemaker, implantable cardioverter-defibrillator or cardiac resynchronization therapy devices. * Interatrial baffle, patent foramen ovale, or atrial septal defect closure device or patch. * Any Left Atrial Appendage Closure or Occlusion Device, except a WATCHMAN™ device implanted \> 90 days before Enrollment 4. Valvular Disease - Presence of any of the following: * Any prosthetic heart valve, ring or repair * Moderate to severe mitral valve stenosis * More than moderate mitral regurgitation (≥ 3+) * Moderate to severe aortic stenosis 5. Cardiomyopathy - Hypertrophic cardiomyopathy 6. Access Issues - Any IVC filter, known inability to obtain vascular access, or other contraindication to femoral access 7. Anticipated Cardiac Surgery - Awaiting cardiac transplantation or other planned cardiac surgery within the next 12 months 3. Congenital Conditions - Any of the following congenital conditions: a. Congenital heart disease with any clinically significant residual anatomic or conduction abnormality 4. Baseline Conditions - Any of the following conditions at Baseline: 1. Heart failure - Heart failure associated with NYHA Class III or IV 2. Ejection Fraction - Most recent documented LVEF \< 40% within the previous 12 months 3. Obesity: Body Mass Index (BMI) \> 45.0 kg/m\^2 4. Hematologic Condition: Known coagulopathy or bleeding disorder 5. Anticoagulation Contraindication: Contraindication to, or unwillingness to use, systemic anticoagulation, or acceptable alternatives, pre-, intra- and post-procedure to achieve adequate anticoagulation 6. Pregnancy - Women who are confirmed to be pregnant or lactating at the time of the ablation procedure 7. Pulmonary Disease - Severe lung disease, severe pulmonary hypertension, or any lung disease involving abnormal blood gases or requiring supplemental oxygen 8. Malignancy - Active malignancy (other than non-melanoma skin cancers) 9. Gastrointestinal - Clinically significant gastrointestinal problems involving the esophagus or stomach, including severe or erosive esophagitis, uncontrolled gastric reflux, gastroparesis, esophageal candidiasis or active gastroduodenal ulceration 10. Infection - Known active systemic infection 11. Sleep Apnea - Untreated diagnosed obstructive sleep apnea with apnea-hypopnea index classification of severe (\> 30 events per hour) as per the guidelines 12. Life Expectancy - Predicted life expectancy of less than one (1) year per investigator medical judgment 13. Concurrent Enrollment - Subjects who are currently enrolled in another investigational study or registry that would directly interfere with the current study, except when the subject is participating in a mandatory governmental registry, or a purely observational registry with no associated treatments; each instance must be brought to the attention of the sponsor to determine eligibility 5. Any of the following events within 90 days of the Consent Date: 1. Coronary disease - Myocardial infarction (MI), unstable angina or coronary intervention 2. Pericardium - Pericarditis or symptomatic pericardial effusion 3. GI Bleeding - Gastrointestinal bleeding 4. Cardiac Surgery - Any cardiac surgery 5. Neurovascular Event - Stroke, TIA, or intracranial bleeding 6. Thromboembolism - Any active non-neurologic thrombus and/or thromboembolic event 7. Carotid Intervention - Carotid stenting or endarterectomy 8. Diabetes - Uncontrolled diabetes mellitus or a recorded HgbA1c \> 8.0% 6. Medical History - Any of the following conditions in the Medical History 1. Transplantation - Solid organ or hematologic transplant, or currently being evaluated for a transplant 2. Diaphragmatic Abnormality - Any prior history or current evidence of hemi-diaphragmatic paralysis or paresis 3. Coronary Disease - Any documented history of Prinzmetal angina or severe non-revascularizable coronary disease 4. Renal Disease - Renal insufficiency if an estimated glomerular filtration rate (eGFR) is \< 30 mL/min/1.73 m2, or with any history of renal dialysis or renal transplant 5. General Medical Conditions - Any other general health conditions that, in the investigator's medical opinion, would prevent participation in the study, interfere with assessment or therapy, significantly raise the risk of study participation, or modify outcome data or its interpretation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Paroxysmal atrial fibrillation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    4 sites in 4 countries. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Klinicki Bolnicki Centar Split

    RECRUITING

    Split, 21 000, Croatia

  • Na Homolce Hospital

    RECRUITING

    Prague, 15030, Czechia

  • Queen Mary Hospital

    NOT_YET_RECRUITING

    Hong Kong, Hong Kong

  • Taipei Veterans General Hospital-Hospital

    NOT_YET_RECRUITING

    Taipei, 1127, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.